HSD17B1 and prostate carcinoma: Furthermore, treatment with inhibitors of 5alpha-reductase type I and type II in prostate cancer cell lines resulted in increased HSD17B1 [84], suggesting a role of DHT in up-regulating HSD17B1 expression in prostate cancer cells.